NeuroOne Medical Technologies, a leading medical technology company dedicated to enhancing surgical care for patients with neurological disorders, has announced the approval of its new patent titled “Agent-Delivering Neural Probe Devices and Related Systems and Methods.” This groundbreaking patent covers a range of electrodes designed to function as standard neural electrodes while also delivering therapeutic agents to targeted areas of the patient’s brain.
The issuance of a Notice of Allowance by the U.S. Patent and Trademark Office (USPTO) signals the successful examination of the patent application and the decision to grant a patent for the innovative neural probe devices. NeuroOne is optimistic about the official issuance of the patent in the coming months.
This latest patent application adds to NeuroOne’s robust portfolio, which already includes two other allowed patent applications, an issued U.S. patent, eight pending U.S. applications, and several foreign applications. The portfolio encompasses a diverse array of thin-film electrode technologies, covering neural and spinal cord electrodes. These electrodes feature unique structures designed to optimize functionality and minimize profile, demonstrating NeuroOne’s commitment to advancing surgical options and improving patient outcomes.
The development of electrodes that not only serve as neural interfaces but also facilitate the delivery of treatment agents represents a significant advancement in neurosurgical technology. This innovation has the potential to enhance precision and efficacy in the treatment of neurological disorders, reflecting NeuroOne’s dedication to pushing the boundaries of medical technology.